CM
CLVS

Castleark Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Castleark Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-126,739
Closed -$3.15M – 411
2019
Q1 		$3.15M Buy
+126,739
New +$3.18M 0.12% 187
2017
Q4 		– Sell
-61,625
Closed -$5.08M – 446
2017
Q3 		$5.08M Buy
61,625
+4,865
+9% +$386K 0.16% 185
2017
Q2 		$5.31M Sell
56,760
-49,905
-47% -$3.05M 0.17% 174
2017
Q1 		$6.79M Buy
+106,665
New +$6.48M 0.21% 155

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Castleark Management's CLVS Position: Q2 2019 in Review

Castleark Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 126,739 shares — an estimated $3.15M sold.

Castleark Management first reported a position in CLVS in Q1 2017 and held it in 4 quarters. The position peaked at $6.79M in Q1 2017. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Castleark Management reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Castleark Management sold 126,739 Clovis Oncology, Inc. shares in Q2 2019, an estimated $3.15M.
  • Castleark Management first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 4 quarters.
  • Castleark Management's Clovis Oncology, Inc. position peaked at $6.79M in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Castleark Management's 13F filing for Q2 2019, filed 13 Aug 2019.